Scholarlink

Background and Objective <p>Venous thromboembolism (VTE) events remain a top cause of morbidity and mortality following bariatric surgery. Thus, prophylactic BMI-tiered low-molecular-weight heparin (LMWH) regimens have been implemented. The adequacy of such prophylaxis has been questioned.&#xa0;The aim of this study was to evaluate the adequacy of BMI-based VTE prophylaxis using the anti-factor Xa (AFXa) assay in patients with obesity undergoing bariatric surgery.</p> Methods <p>This was a retrospective review of adult patients undergoing Roux-en-Y gastric bypass (RNYGB), laparoscopic sleeve gastrectomy (LSG), or revisional bariatric procedures, at a high-volume, community-based institution, between January 2017 and December 2020. Patients received twice daily, BMI-tiered dosing of LMWH post-operatively. Individuals with BMI &lt; 50&#xa0;kg/m<sup>2</sup> received 40-mg LMWH; those with BMI ≥ 50&#xa0;kg/m<sup>2</sup> received 60-mg LMWH. AFXa levels were analyzed 4–6&#xa0;h following the second or subsequent dose. Levels of 0.2–0.4&#xa0;IU/mL were considered prophylactic.</p> Results <p>A total of 203 patients (67% female) were included. Median age and BMI were 46&#xa0;years and 50.79&#xa0;kg/m<sup>2</sup>, respectively. Seventy-two percent of patients underwent RNYGB. Ultimately, 37% of patients did not achieve adequate prophylaxis; 23% were supra-prophylactic. Ninety patients had BMI &lt; 50. Of these, 17 were supra-prophylactic and 16 sub-prophylactic. One hundred-thirteen patients had BMI ≥ 50. Of these, 29 were supra-prophylactic and 14 sub-prophylactic. Adequacy of dosing did not differ significantly based on patient demographics.</p> Conclusion <p>BMI-tiered LMWH dosing for VTE prophylaxis in this bariatric surgery population was inadequate in achieving prophylaxis in greater than 37% of patients. This rate is substantially different than previous reports.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Analyzing the Adequacy of BMI-Tiered Enoxaparin Dosing for Venous Thromboembolism Prophylaxis in the Bariatric Surgery Population Based on Anti-Factor Xa Assay Data

  • 期刊论文

  • 发表日期：

    2025年7月4日

查看全文
  • Blake O’Connor,
  • Katherine Meister,
  • Angela Fellner,
  • Tiffany Isaacs

摘要

Background and Objective

Venous thromboembolism (VTE) events remain a top cause of morbidity and mortality following bariatric surgery. Thus, prophylactic BMI-tiered low-molecular-weight heparin (LMWH) regimens have been implemented. The adequacy of such prophylaxis has been questioned. The aim of this study was to evaluate the adequacy of BMI-based VTE prophylaxis using the anti-factor Xa (AFXa) assay in patients with obesity undergoing bariatric surgery.

Methods

This was a retrospective review of adult patients undergoing Roux-en-Y gastric bypass (RNYGB), laparoscopic sleeve gastrectomy (LSG), or revisional bariatric procedures, at a high-volume, community-based institution, between January 2017 and December 2020. Patients received twice daily, BMI-tiered dosing of LMWH post-operatively. Individuals with BMI < 50 kg/m2 received 40-mg LMWH; those with BMI ≥ 50 kg/m2 received 60-mg LMWH. AFXa levels were analyzed 4–6 h following the second or subsequent dose. Levels of 0.2–0.4 IU/mL were considered prophylactic.

Results

A total of 203 patients (67% female) were included. Median age and BMI were 46 years and 50.79 kg/m2, respectively. Seventy-two percent of patients underwent RNYGB. Ultimately, 37% of patients did not achieve adequate prophylaxis; 23% were supra-prophylactic. Ninety patients had BMI < 50. Of these, 17 were supra-prophylactic and 16 sub-prophylactic. One hundred-thirteen patients had BMI ≥ 50. Of these, 29 were supra-prophylactic and 14 sub-prophylactic. Adequacy of dosing did not differ significantly based on patient demographics.

Conclusion

BMI-tiered LMWH dosing for VTE prophylaxis in this bariatric surgery population was inadequate in achieving prophylaxis in greater than 37% of patients. This rate is substantially different than previous reports.